Phage integrases for the construction and manipulation of transgenic mammals
© Hollis et al; licensee BioMed Central Ltd. 2003
Received: 15 July 2003
Accepted: 07 November 2003
Published: 07 November 2003
Phage integrases catalyze site-specific, unidirectional recombination between two short att recognition sites. Recombination results in integration when the att sites are present on two different DNA molecules and deletion or inversion when the att sites are on the same molecule. Here we demonstrate the ability of the φC31 integrase to integrate DNA into endogenous sequences in the mouse genome following microinjection of donor plasmid and integrase mRNA into mouse single-cell embryos. Transgenic early embryos and a mid-gestation mouse are reported. We also demonstrate the ability of the φC31, R4, and TP901-1 phage integrases to recombine two introduced att sites on the same chromosome in human cells, resulting in deletion of the intervening material. We compare the frequencies of mammalian chromosomal deletion catalyzed by these three integrases in different chromosomal locations. The results reviewed here introduce these bacteriophage integrases as tools for site-specific modification of the genome for the creation and manipulation of transgenic mammals.
The ability to manipulate the mammalian genome in vivo is important in many areas of research. There is a growing need for site-specific recombinases that function in the mammalian environment to catalyze genomic integration and excision, for example in the construction of transgenic organisms and the study of gene function in vivo. The site-specific integrases of bacteriophages φC31, R4, and TP901-1 have been shown to function in human and mouse cells to catalyze excision on extrachromosomal vectors and chromosomal integration [1–4]. Phage φC31 integrase has been applied to achieve chromosomal integration in gene therapy studies [5–9]. These results suggested that these site-specific integrases would likely function in the mammalian embryonic environment and could have utility in the creation of transgenic animals and manipulation of the mammalian genome in vivo. The use of bacteriophage integrases in mammalian transgenesis is a new field. This article will discuss some of the potential applications of site-specific integrases in this area and the preliminary results our lab has obtained to date.
Site-Specific Integration for the Construction of Transgenic Mammals
Transgenic mammals are an essential component of biotechnology, having a wide variety of applications ranging from gene knockout studies to serving as living bioreactors. A common method of transgenic mammal production relies on microinjection of DNA directly into the pronucleus of a single-cell embryo, with genomic insertion generally resulting by random integration. Alternatively, mouse embryonic stem (ES) cells can be modified by homologous recombination and placed into a developing embryo. The latter approach results in a mosaic animal that may or may not have germ cells modified. Random integration and homologous recombination both occur at low frequencies (10-4 and 10-6, respectively). Other methods have been developed for DNA delivery and maintenance in ES cells including mammalian artificial chromosomes [10, 11], retroviruses [12–14], and the Sleeping Beauty transposon . Nuclear transfer from more mature cells can also be used to introduce a new genome for a developing embryo, and this nuclear DNA can be first modified by any of the above methods [16, 17].
The available technologies are hindered in that gene insertion is often random. In the resultant transgenic animals, the expression levels of the genes of interest are influenced by context factors that are difficult to control. For example, some influencing factors include the regulatory and bacterial elements in the insertion construct itself , the position of the insertion in the genome , and the number of integrated constructs [19, 20]. Production of a desired clone often takes many rounds of screening. Following screening there may be additional problems caused by the transgene insertion resulting in sterility or pre-adolescent lethality, preventing preservation of the newly developed strain. Efficient, targeted single copy integrations would be helpful for the improvement of transgenic animal production. Site-specific integration systems could potentially be useful in this context. A bacteriophage integrase, such as that of phage φC31, can be used to integrate a donor plasmid into the mammalian genome, and integrants can be screened by a simple PCR reaction to identify integrations into known and desirable targets. A quantitative PCR approach can be used to ensure that only single integration events are selected. In the creation of multiple transgenic animal lines, candidate clones can be screened and selected so that the genomic integration event in each animal line is in the identical genomic location and orientation, thereby eliminating positional effect differences between the different transgenic lines. Any genomic location is likely to exert context effects that affect the expression of an integrated transgene, but the use of a site-specific integration system will help to ensure that these effects are not varied among different lines. To date, site-specific recombinases have not been used for the creation of transgenic mammals, though some, such as Cre, have been valuable for genomic manipulations in transgenic animals, as discussed below.
Phage Integrase Biology in the Mammalian Environment
Members of the serine family of site-specific recombinases , including integrases from phages φC31 [1, 2, 5, 6, 9], R4 , and TP901-1 , are good candidates for mammalian genomic modification. In nature, each integrase recognizes a sequence in the phage genome, the phage attachment site attP. Each integrase also recognizes a bacterial attachment site, attB, in the bacterial genome. Integrases of the serine family of recombinases are capable of recombining these short attP and attB attachment sites, whose minimal sizes are 35–50 bp. The products, two hybrid sites, attL and attR, are no longer substrates for recombination by the integrase, so the reactions are unidirectional . While the integrase alone can only catalyze a recombination between an attP and an attB site, the result of the recombination can vary based on the location and orientation of these two att sites. When located on different DNA molecules, recombination between an attP and an attB results in an integration event. However, if the two sites are located on the same DNA molecule (plasmid or chromosome), two outcomes are possible: if the attP and the attB are in the same orientation on the DNA, the net result will be a deletion event; if the two att sites are in opposite orientations, the net result will be an inversion. Thus, by knowing the locations and orientations of compatible att sites, specific recombination events can be created and selected for.
We have demonstrated that the φC31 integrase is able to mediate efficient integration of attB-bearing plasmids into the human and mouse genomes, at inserted wild-type attP sites and at endogenous "pseudo" attP sites that have partial identity to attP . We previously identified 26 pseudo attP sites in the human genome, and 57 pseudo attP sites in the mouse genome . We have not detected the presence of pseudo attB sites in mammalian genomes, which should reduce the likelihood that endogenous genomic sequences are inadvertently deleted during an integration attempt. There may not be pseudo attB s that could be recognized and recombined with a pseudo attP by the integrase.
Site-Specific Chromosomal Deletions
In addition to chromosomal integration events, often times a chromosomal deletion is desired, such as in the generation of knockout transgenic animals. One way to accomplish deletion of a sequence of interest is through the use of site-specific recombinases, such as the Cre recombinase of coliphage P1 and its loxP recognition sites . The deletion can be precisely confined to a specific developmental time or tissue, based on control of recombinase expression. This outcome is most commonly achieved by creating a transgenic mouse that contains the gene of interest flanked by loxP sites, and then crossing that mouse with a Cre-expressing mouse . The Cre gene may, for example, be under a tissue-specific promoter. Once crossed, the gene of interest will be deleted in all cells in which Cre is expressed, thereby generating a tissue-specific knockout [24–30]. The same approach can be used to activate a gene of interest, by inserting a stop cassette between the promoter and the gene of interest and flanking the stop cassette with loxP sites . If the gene knockout is desired in the entire animal, the "floxed"-transgene mouse oocytes can be transfected with a Cre-expression plasmid or Cre mRNA, so that expression is transient, but sufficient to delete the gene of interest at an early developmental stage, thereby producing an animal devoid of the gene of interest [32, 33].
Alternatively, excision can be controlled in a temporal-specific manner by expressing Cre from an inducible promoter. A fusion protein of Cre recombinase and a mutated hormone-binding domain of the murine estrogen receptor showed temporal-specific activity in transgenic mice that was controlled by the presence of tamoxifen . Temporal-specific recombination has also been accomplished by driving Cre expression from inducible promoters, such as a tetracycline-inducible promoter . Simultaneous temporal- and tissue-specific Cre expression has been demonstrated using tissue-specific promoters to drive expression of the Cre ORF fused to a hormone receptor ligand-binding domain [29, 36].
Some circumstances require more complicated deletion/insertion events, such as sequential gene inactivation and exon swapping . Additionally, it may be desirable to remove extraneous sequences in an integrated vector, such as bacterial or mammalian drug selection markers . The FLP recombinase from the 2 μm plasmid of S. cerevisiae has been used in transgenic mice as an alternative to Cre [38, 39] and in combination with Cre , although FLP functions at only ~10–25% efficiency compared to Cre in generating chromosomal deletions . The Cre and FLP recombinases are the only two enzymes currently available for genomic manipulation experiments, making complicated experimental schemes difficult to perform [25, 40]. The increasing desire to perform complex genomic manipulations creates a need for additional site-specific recombinase tools that function efficiently in the mammalian chromosomal environment.
Phage φC31 Integrase Functions in the Mouse Embryonic Environment and Mediates Genomic Integration
To demonstrate that the φC31 integrase would be functional in the embryonic environment, single-cell embryos of the FVB/NacfBR mouse strain were injected with 3 ng/μl nucleic acid solutions directly into the pronucleus. Two groups of injected embryos were studied. One group received pCMVInt plasmid DNA  as a source of integrase (n = 31), and the other received φC31 integrase mRNA (n = 32). Both groups were co-injected with the intramolecular-integration assay vector pBCPB  carrying attB and attP sites. The embryos were frozen at the two-cell stage, total DNA was extracted , and the expected wild-type attL junction was PCR amplified from recombined plasmid. A product of correct size was observed in both groups of embryos. This product is specific for the recombination event and is not present unless φC31 integrase is expressed . Embryos co-injected with integrase mRNA produced a band of correct size with just ~25% of the template that was required to detect the same band from the pCMVInt/pBCPB injections. This result suggested that integrase mRNA was more efficient in the embryonic environment than DNA, presumably due to the elimination of the requirement for transcription. This result was consistent with observations that injection of Cre mRNA into mouse oocytes provided efficient Cre activity in vivo . The use of mRNA instead of DNA also precluded undesirable integration of the integrase gene by random integration.
Phage φC31 integrase can efficiently catalyze a site-specific cassette exchange reaction using introduced wild-type att sites in mouse ES cells  and can recognize and insert attB-containing plasmids into pseudo attP sites in the murine genome [2, 6]. A hotspot for φC31 integrase-mediated integration was identified in hepatocytes on chromosome 2 (GenBank: AC 079573) and named mpsL1 (m ouse p seudo attP s ite in l iver) . Integration at mpsL1 was also detected in mouse NIH3T3 cells , indicating that mpsL1 may be a preferred integration site in the mouse genome. A GFP vector, pEGFPB2, carrying an attB site was injected into one-cell embryos either with (n = 35) or without (n = 27) φC31 integrase mRNA. GFP expression was used to indicate visually the number of embryos with integrated DNA, because non-integrated DNA should be gradually lost during a 5 day period of rapid cell division to the multi-cell or blastocyst stage. By fluorescent microscopic analysis, the two groups had similar numbers of detectibly GFP-positive embryos, 6/35 with integrase and 5/27 without integrase. Embryos were positive for GFP expression in all cells; however, the group that received the integrase mRNA contained embryos with an overall more intense green fluorescence.
Construction Of Site-Specific Integrant Transgenic Animals
FVB/NacfBR transgenics obtained following injection with attB hFIX-containing vector with or without φC31 integrase mRNA.
ng/μl attB DNA/Integrase mRNA
3 DNA + 0 mRNA
3 DNA + 3 mRNA
3 DNA + 6 mRNA
A mid-gestation mouse found to have a plasmid inserted site-specifically in its genome was further studied by PCR and sequence analysis. Using a nested PCR rescue technique , it was determined that this animal contained the donor plasmid site-specifically integrated into a sequence on chromosome 4 termed mpsT1 (m ouse p seudo attP s ite in T ransgenic 1), shown in Figure 1B. This integration site is located in the last intron of a putative gene detected in a 16-day neonate (Genbank: AK052928). The integration event did not prevent embryogenesis in this experiment, indicating that an integration event at mpsT1 was unlikely to disrupt development and this location was potentially a suitable target site for future transgene integrations. Like the mpsL1 pseudo site, mpsT1 has limited identity to the wild type attP sequence (Figure 1B). Chromatin structure may influence which pseudo sites are used . Repeatedly targeting an identical genomic locus such as mpsT1 could allow for the creation of multiple transgenic lines with transgenes integrated at the same, predictable genomic locus. Creation, by directed evolution , of integrases with tighter site-specificity may allow for such a possibility.
The use of an engineered mouse strain containing an inserted wild-type attP site could help resolve position effects by providing a method to preferentially target transgenes to a predetermined location. The use of an attP transgenic mouse strain might also increase the integration frequency, because the integrase might work more efficiently at a perfect attP site, compared to pseudo attP sites. The detection of site-specific integrants would also be simplified because the sequence of the target site was known. Therefore, similar experiments were performed on a strain of transgenic mice we prepared that contained a wild-type φC31 attP site. Injections into this attP-bearing mouse strain were performed with φC31 mRNA and the attB donor plasmid pBChFIXattB. Of 7 injected pups that carried the wild-type attP site, none were found to have an insertion of the attB donor plasmid anywhere in their genomes. Although the number of pups examined was low, this negative result may indicate a poor genomic location of the φC31 attP site in this transgenic strain, with respect to chromatin access for the φC31 integrase. The creation of a strain with a more accessible attP site might result in a higher percentage of φC31-mediated integrations at the attP site.
Chromosomal Deletions Catalyzed by Phage Integrases
Quantitative PCR analysis of TP901-1 integrase-catalyzed deletion was unsuccessful. The TP901-1 attR is highly A+T-rich, making Taqman primer/probe design difficult. Because we could not accurately determine TP901-1 deletion frequency by qPCR, Southern blot analysis was performed. This analysis was done for φC31 and R4 as well, in order to directly compare with the TP901-1 frequency and to independently verify the deletion frequency determined by qPCR. Genomic DNA from integrase-transfected cell lines was analyzed by Southern blot, and deletion frequency was quantified. Chromosomal recombination resulted in reduction of the genomic vector by deletion of 4.8 kb (φC31), 3.7 kb (R4), or 4.2 kb (TP901-1) of intervening vector sequence. Representative Southern blots of φC31-, R4-, and TP901-1-transfected cell line genomic DNA are shown in Figure 3B. Quantification of band intensity indicated that Southern analysis of chromosomal deletion frequency was in agreement with that calculated by qPCR analysis for the φC31 and R4-transfected cell lines.
The φC31 integrase consistently performed more efficiently than the R4 and TP901-1 integrases. In cell line 293-3BP3, chromosomal deletion was catalyzed by the φC31 integrase with an average frequency of 51%, by the R4 integrase at an average frequency of 37%, and by the TP901-1 integrase at a frequency of 39%. The R4 and TP901-1 integrases performed equally well, though at a lower frequency than the φC31 integrase, in cell line 293-3BP6. The frequency of deletion catalyzed by the φC31 and R4 integrases was lower in all other cell lines to varying degrees, while TP901-1 integrase showed no measurable activity in these other cell lines.
The chromosomal deletion frequency of the φC31 integrase ranged from 51% in cell line 293-3BP3 to only 1.7% in the 293-3BP8 cell line. Similar ranges were observed for the R4 integrase. These variations in activity most likely represented a chromosomal position effect of the integrated vectors in different regions of the genome, which may affect the ability of the integrase to efficiently access the att sites. We have hypothesized that the φC31 integrase preferentially integrates into pseudo attP sites that are in actively expressed regions; an open chromatin configuration may be required for efficient targeting and recombination by the integrase . This hypothesis was supported by the apparent chromosomal position effects on excisive recombination observed here. The TP901-1 integrase appeared to be even more susceptible to chromosomal position effects, as evidenced by its ability to perform deletions at ~35% efficiency in two of the cell lines, the two with the highest deletion frequencies by φC31 and R4 integrases, but its lack of deletion formation in the other cell lines analyzed.
The experiments reported here suggest that the φC31 integrase can be used to create transgenic mice carrying site-specific transgene insertions. The numbers of φC31-mediated transgenic animals generated were low, with approximately 2.6% of harvested pups representing φC31 integrase-mediated transgenic animals, in the best experiment. Our sequence data demonstrated that the φC31 integrase functioned in the embryonic nuclear environment to integrate plasmid DNA site-specifically into the genome. Additional experiments with greater numbers of animals will be required to optimize the procedure and determine the efficiency of such an approach for generating transgenic mammals. Such a tool would be beneficial because the genomic location of the integration site, either at an inserted wild-type attP site or at a known endogenous pseudo attP site, can be specifically detected by PCR amplification, potentially allowing the creation of multiple transgenic lines with different integrated transgenes in the same genomic context. This feature would permit creation and comparison of multiple transgenic animal strains without confounding chromosomal position effects. The φC31 integrase has also been shown to function at efficiencies of ~50% for creation of transgenic Drosophila at inserted attP sites [Groth, A.C., Fish, M., Nusse, R., and Calos, M.P., submitted]. This integrase is therefore likely to be of use in construction of a wide range of transgenic species.
We also demonstrated that the integrases of bacteriophages φC31, R4, and TP901-1 performed efficiently in creating intrachromosomal deletions and should be of great value for manipulating mammalian genomes, both in vitro and in vivo. The maximum observed deletion frequencies presented here were in the range of 30–50%, but this range probably underestimates the activity of these integrases. The criteria used for sorting GFP-positive, integrase-transfected cells may have included untransfected cells. Following expansion of these cells, quantitative analysis of chromosomal deletion frequency would be depressed by the presence of cells that were never exposed to integrase. However, even at the observed frequencies of 30–50%, the φC31, R4, and TP901-1 integrases constitute efficient tools for the manipulation of mammalian chromosomes. In the experiments reported here, the φC31, R4, and TP901-1 integrases used were in their native prokaryotic form, with no addition of an NLS. A φC31-NLS integrase  may function significantly better, nearing 100%, in this chromosomal deletion assay, and addition of an NLS may have a similar positive effect on the efficiencies of the R4 and TP901-1 integrases. Such chromosomal deletion frequencies would make the φC31, R4, and TP901-1 integrases equivalent to Cre recombinase and valuable as molecular tools for mammalian chromosome engineering. Additional experiments will need to be conducted in order to determine the efficiency of these integrases in catalyzing chromosomal deletions in vivo. These serine family site-specific phage integrases clearly constitute new and valuable tools for genome engineering.
Materials and Methods
Transgenic Animal Experiments
The φC31 integrase gene was amplified to include the Nde I restriction site from pTA-Int  by using the primers "Native 5' NdeI (+)" (CGA CTA GTC ATA TGG ACA CGT ACG CGG GTG CT) and "3' BamHI φC31" (AGC CGG ATC CGG GTG TCT CGC TA). The pET11 vector (Novagen, Madison, WI) received the amplified φC31 integrase gene directionally inserted into Nde I and Bam HI sites so that the T7 promoter drove φC31 integrase mRNA production (pET11φC31). The oligonucleotides Bam HI-polyA-top (GAT CGC GCC AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA CCG) and Bam HI-polyA-bottom (GAT CCG GTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TGG CGC) were annealed, digested with Bam HI, and inserted into the Bam HI site in pET11φC31 to create pET11φC31polyA. The assay construct pEGFPB2 is based on the vector pEGFP-N2 (Clontech, Palo Alto, CA). A lac promoter to drive GFP expression in bacteria and codons for the first 26 amino acids of β-galactosidase were cloned into the Nhe I and Hind III sites within the multicloning site of pEGFP-N2, placing it in frame with eGFP to create pCMVlac GFP. The attB fragment was released from pTA-attB  with Eco RI, and the ends of the fragment were blunted. The blunt attB fragment was inserted into pCMVlacGFP vector blunted at the Dra III restriction site. This cloning of the attB with the TT core pointing towards the GFP terminator sequence resulted in creation of the assay vector pEGFPB2.
Nucleic acid preparations for microinjection
The φC31 integrase mRNA was transcribed from the vector pET11φC31polyA using the mMessage mMachine (Ambion, Austin, TX). φC31 RNA and DNA were purified and diluted in microinjection TE (miTE) buffer (10 mM Tris and 0.1 mM EDTA, pH 7.4) to reach a final concentration of 3 ng/μl. For the injections 3 or 6 ng/μl solutions of each nucleic acid were used.
PCR screening for integration
Standard embryo DNA retrieval technique for PCR was employed . The primers attBF2 (ATG TAG GTC ACG GTC TCG AAG C) and attP1+ (TGG CGG CCG CTC TAG AAC TA) were used to specifically amplify the wild type attL junction in integrase-reacted pBCPB. A 175 bp product will be amplified. For detection of mpsL1 integration in embryos, a primary PCR using the primers attBF3 (CGA AGC CGC GGT GCG) and mpsL1-R2 (GTA AAT GTT ATT GCG GCT CT) was purified and used as a template in a secondary PCR using attBF3 and the nested primer mpsL1-R1 (TGA GGA GGA GCC TTA GCA AC). The secondary PCR amplifies a nested product of 208 bp. For detection of the GFP transgene, the primers GFPfor (CTG GAC GGC GAC GTA AAC GGC CAC) and GFPrev (GGC GGA TCT TGA AGT TCA CCT TC) were used to specifically amplify a 453 bp segment of the GFP transgene. The hFIX positive cells were identified using the primers hFIXend (CAC TTC TGG AGG CCA AGG TGG G) and att BRF2-com (GCT TCG AGA CCG TGA CCT ACA TC), resulting in a 406 bp band being amplified. To identify φC31-mediated transgenics, the primers hFIXend and attBR2 (TCA ACT ACC GCC ACC TCG AC) were used, which provide a 508 bp product only if an intact attB is present. To detect the presence of an attP segment in transgenic mice, the primers For4TRI (AAC TCA GTT GGG CTC AAT TCC) and the Revr4TRI (CCA GTA GCT GAC ATT CAT CCG) were used to amplify a specific 1559 bp product.
PCR detection of integration into pseudo attP sites
To detect integration at mpsL1 in pups, attBF3 and mpsL1-R2 were used in a PCR reaction. Positive integrants at mpsL1 resulted in a 513 bp product. To discover unidentified pseudo attP sites, genomic DNA was digested using: Avr II, Nhe I, Spe I and Xba I. The genomic digests were ligated to produce circularized substrate for inverse PCR. The attL junctions were amplified using attBF2 and hFIXinvR1 (CAT CAA ATA CAG GGT GAC TGA TTC). A nested reaction was then applied to increase specificity using the primers attBF3 and hFIXinvR2 (CAA AGG GAA ACA TAC GTC AG). Resulting bands were cloned and sequenced.
Wild-type attP transgenic mice
The plasmid pTA-attP333  carries the full length TP901-1 attP site. The φC31 attP site was isolated as a blunted Spe I fragment from pBCPB  and ligated into the blunted Ava I site of pTA-attP333, creating the plasmid pBI(-). The R4 attP site was isolated from the plasmid pBCRattP64  by digestion with Pvu II and Sna BI and blunt-ending with T4 polymerase. It was then ligated into the Dra III pf pBI(-), creating the plasmid pTRI(+). pTRI(+) was digested with Bgl II and Hin dIII to liberate a 1.9-kb fragment containing the three attP sites. This triple-attP fragment was gel isolated and purified using the QIAexII gel extraction kit (Qiagen, Valencia, CA) and eluted with miTE (10 mM Tris-HCl, 0.1 mM EDTA, pH7.4). DNA was prepared to a concentration of 25 ng/μL. To eliminate debris from the prep, the DNA was passed through a small 0.45 μm Millipore spin filter (Millipore, Billerica, MA). DNA was transferred to the Stanford Transgenic Research Facility for standard transgenic animal production by microinjection.
Chromosomal Deletion Experiments
The assay plasmid for detecting chromosomal deletions was generated as follows. Plasmid pBB-B304-P333 has been described  and will be referred to as pBB-TP(BP). This plasmid contains the full-length TP901-1 attP and attB recognition sites flanking the 3.5 kb lacZ gene. The 64 bp R4 attP site was generated by kinasing and annealing the oligonucleotides 5'-CCGGGCATGTTCCCCAAAGCGATACCACTTGAAGCAGTGGTACTGCTTGTGGGTACACTCTGCGGGTGTAC-3' and 5'-CCGGGTACACCCGCAGAGTGTACCCACAAGCAGTACCACTGCTTCAAGTGGTATCGCTTTGGGGAACATGC-3', followed by ligation into the Xma I site of pBB-TP(BP), creating the plasmid pBB-TP(BP)-R4(P). Into the Sac II site of this plasmid, the 224 bp φC31 attP site was cloned as an Xba I-Sca I fragment from plasmid pBCPB+ , resulting in the plasmid pBB-TP(BP)-R4(P)-φC31(P). Into the Xho I site of this plasmid, the 313 bp φC31 attB site was cloned as an Xho I fragment released from pBCPB+, generating plasmid pBB-TP(BP)-R4(P)-φC31(BP). Into the Bam HI site of this plasmid, the 295 bp R4 attB site was ligated as an Xho I fragment released from the plasmid pBC-R4PB , creating the plasmid pBB-TP(BP)-R4(BP)-Phi(BP). Lastly, a 2.0 kb Sal I-Nru I fragment from pEF , encoding the gene for hygromycin resistance driven by the TK promoter, was cloned into the Age I site of pBB-TP(BP)-R4(BP)-φC31(BP), generating the assay plasmid pBB-TP(BP)-R4(BP-φC31(BP)-Hyg, referred to as plasmid p3BP.
Each integrase was independently cloned into the expression plasmid pIRES-hrGFP-1a (Stratagene, La Jolla, CA). The TP901-1 integrase was cloned into the Eco RI-Xho I sites of pIRES-hrGFP-1a as a 1.5 kb EcoR I-Xho I fragment from pCS-TPInt , generating the plasmid pTP-I-hrGFP. A 1.4 kb Eco RI fragment from pTA-sre , containing the R4 integrase, was cloned into the Eco RI site of pIRES-hrGFP-1a, creating the expression plasmid pR4-I-hrGFP. The φC31 integrase was cloned from pCSI  as a 1.9 kb blunted Spe I-Bam HI fragment and ligated into the Sma I-Bam HI sites of pIRES-hrGFP-1a, to generate the vector pφ-I-hrGFP. Each of these vectors expresses integrase under the control of the CMV promoter, followed by an internal ribosome entry site (IRES) and the humanized Renilla reniformis GFP (hrGFP) open reading frame.
As a standard control for qPCR, the att R junction for each integrase and a hygromycin gene region were cloned into a single plasmid. Vector p3BP was transformed into E. coli strain DH-Int, which expresses the φC31 integrase , in order to generate a φC31-excised plasmid. The attR was PCR amplified and TOPO-cloned into vector pCR2.1 (Invitrogen, Carlsbad, CA), creating the plasmid pTA-φex. Next, the R4 attR was generated by intramolecular integration reaction in 293 cells co-transfected with p3BP and pCMV-sre , creating p3BP-R4ex. The R4 attR junction was PCR amplified from p3BP-R4ex with primers that added Spe I sites to each end of the attR. The PCR product was digested with Spe I and ligated into the Spe I site of pTA-φex, creating plasmid pTA-φex-R4ex. The TP901-1 attR junction was generated by transforming p3BP into DH-TPInts , generating plasmid p3BP-TPex. The TP901-1 attR was then PCR amplified, with addition of Bam HI sites to each end. The PCR product was digested with Bam HI and ligated into the Bam HI site of pTA-φex-R4ex, creating the plasmid pTA-φex-R4ex-TPex. Next, a region of human Rad52 gene was PCR amplified from 293 genomic DNA with primers that added Cla I sites to each end. The PCR product was digested with Cla I and ligated into the Cla I site of pTA-φex-R4ex-TPex, creating the plasmid pTA-3attR-Rad52. Finally, a portion of the hygromycin gene encompassing the qPCR amplification region was PCR amplified from p3BP, digested with Xba I, and ligated into the Xba I site of pTA-3attR-Rad52, generating the standard vector p3attR-Rad52-Hyg. This vector was linearized with Xcm I, purified, and serially diluted for use in qPCR to generate a standard curve.
Plasmid p3BP was digested with Xmn I to generate a linear molecule. Five μg of linearized p3BP plasmid was electroporated into 293 cells using a Bio-Rad Gene Pulser according to the manufacturer's recommendations. The cells were then allowed to recover in nonselective Dulbecco's modified eagle medium, supplemented with 9% FBS and 1% penicillin-streptomycin. After 24 h, the cells were placed under selection using medium containing 200 μg/ml hygromycin B (Calbiochem, La Jolla, CA). After 14–21 d under selection, single, well-isolated colonies were picked and expanded. All cell lines were screened for the presence of intact triple-attP and triple-attB sites by PCR and by Southern analysis. Six 293-3BP cell lines were selected for further analysis.
Chromosomal deletion assay
293-3BP cell lines were transfected with 5 μg of pInt-I-hrGFP plasmid using Fugene 6 (Roche Applied Scientific, Indianapolis, IN), according to manufacturer's protocol. At 72 h post-transfection, GFP-positive cells were sorted and collected using a MoFLoPs FACS machine, thus sorting for cells that received integrase expression plasmid. Approximately 15 d after sorting and expansion, cells were harvested and genomic DNA was prepared using the Blood and Cell Culture DNA Maxi Kit (Qiagen, Valencia, CA).
Quantitative PCR analysis
Quantitative PCR on genomic DNA was performed using the following primer/probe combinations: TP901 attR: fwdTPex-qPCR 5'-TGATGTTACTGCTGATAATGTAGATATCATAT-3', revTPex-qPCR 5'-ATTAAAATTCACGGAAGAAAGCTTT-3', TPEx-attR-probe 5'-CGAGTTTTTATTTCGTTTATTTCAATCAAGGTAAATGC-3'; Φ C31 attR: fwdPhiEx-qPCR 5'-GGCTTCACGTTTTCCCAGGT-3', revPhiEx-qPCR 5'-CCAGATGGGTGAGGTGGAGT-3', PhiEx-attR-probe 5'-CTGGGGTAACCTTTGGGCTCCCCG-3'; R4 attR: fwdR4ex-qPCR 5'-TCTCATGCATAGAAGGCCCG-3', revR4ex-qPCR 5'-GGCTACACGGAGCAGGACC-3', R4ex-attR-probe 5'-CGATACCACTTGAAGCAGTGGTAGAAGGGCAC-3'. The hygromycin resistance gene was also amplified as an internal control for integrated p3BP vector, using the following primer/probe combination: fwdHyg-qPCR 5'-CTCGGAGGGCGAAGAATCTC-3', revHyg-qPCR 5'-GCAGCTATTTACCCGCAGGA-3', Hyg-probe 5'-TCAGCTTCGATGTAGGAGGGCGTGG-3'. Each of these probes was 5' labeled with the fluorophore 6-FAM and 3' labeled with the quencher TAMRA.
In addition to the primers and probes described above, PCR reagents used were from the TaqMan PCR Core Reagent Kit (Applied Biosystems, Foster City, CA). Amplification was performed in an ABI 7700 machine and the results were analyzed using SDS v1.7 software (Applied Biosystems). Each sample and standard was analyzed in triplicate.
Genomic DNA was digested overnight with Hin dIII. Twenty μg of digested genomic DNA was loaded onto a 0.6% TBE agarose gel and separated. The gel was depurinated in 0.25 M HCl, denatured in 0.5 M NaOH, neutralized in 0.5 M Tris-HCl (pH7.0), and transferred to an S&S Nytran blotting membrane (Schleicher & Shuell, Keene, NH) in 20X SSC transfer buffer. The membrane was probed with a 1.6 kb fragment from the hygromycin resistance gene or with a 1.6 kb genomic fragment from 8p22 encompassing φC31 human pseudo attP site A (hpsA) , both labeled with 32P by random primer extension, using the Ready-To-Go DNA Labeling Kit (-dCTP) (Amersham Pharmacia Biotech). Hybridization occurred at 65°C for ~20 h in Church buffer (1% BSA, 1 mM EDTA, 0.5 M NaHPO4 pH 7.2, 7% SDS). Membranes were washed in 2x - 0.2x SSC at 65°C. Membranes were exposed to a phosphor screen and analyzed using a Storm 840 PhosphorImager (Molecular Dynamics, Sunnyvale, CA). Southern blot quantification was performed using Kodak 1D software.
This work was supported by NIH grants HL68112 and DK58187 to MPC and by the Stanford Transgenic Research Facility.
- Groth AC, Olivares EC, Thyagarajan B, Calos MP: A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci U S A. 2000, 97: 5995-6000. 10.1073/pnas.090527097.PubMed CentralView ArticlePubMed
- Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP: Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol. 2001, 21: 3926-3934. 10.1128/MCB.21.12.3926-3934.2001.PubMed CentralView ArticlePubMed
- Olivares EC, Hollis RP, Calos MP: Phage R4 integrase mediates site-specific integration in human cells. Gene. 2001, 278: 167-176. 10.1016/S0378-1119(01)00711-9.View ArticlePubMed
- Stoll SM, Ginsburg DS, Calos MP: Phage TP901-1 site-specific integrase functions in human cells. J Bacteriol. 2002, 184: 3657-3663. 10.1128/JB.184.13.3657-3663.2002.PubMed CentralView ArticlePubMed
- Olivares EC, Calos MP: Phage C31 Integrase-Mediated Site-Specific Integration for Gene Therapy. Gene Therapy, Regulation. 2003,
- Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP: Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol. 2002, 20: 1124-1128. 10.1038/nbt753.View ArticlePubMed
- Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA: Stable nonviral genetic correction of inherited human skin disease. Nat Med. 2002, 8: 1166-1170. 10.1038/nm766.View ArticlePubMed
- Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA: PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther. 2003, 14: 923-928. 10.1089/104303403765701204.View ArticlePubMed
- Groth AC, Calos MP: Phage integrases: biology and applications. Journal of Molecular Biology. 2003,
- Huxley C: Mammalian artificial chromosomes and chromosome transgenics. Trends Genet. 1997, 13: 345-347. 10.1016/S0168-9525(97)01256-0.View ArticlePubMed
- Wang B, Lazaris A, Lindenbaum M, Stewart S, Co D, Perez C, Drayer J, Karatzas CN: Expression of a reporter gene after microinjection of mammalian artificial chromosomes into pronuclei of bovine zygotes. MolReprod Dev. 2001, 60: 433-438. 10.1002/mrd.1107.abs.View Article
- Nagano M, Brinster CJ, Orwig KE, Ryu BY, Avarbock MR, Brinster RL: Transgenic mice produced by retroviral transduction of male germ-line stem cells. Proc Natl Acad Sci U S A. 2001, 98: 13090-13095. 10.1073/pnas.231473498.PubMed CentralView ArticlePubMed
- Nagano M, Watson DJ, Ryu BY, Wolfe JH, Brinster RL: Lentiviral vector transduction of male germ line stem cells in mice. FEBS Lett. 2002, 524: 111-115. 10.1016/S0014-5793(02)03010-7.View ArticlePubMed
- Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D: Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002, 295: 868-872. 10.1126/science.1067081.View ArticlePubMed
- Dupuy AJ, Clark K, Carlson CM, Fritz S, Davidson AE, Markley KM, Finley K, Fletcher CF, Ekker SC, Hackett PB, Horn S, Largaespada DA: Mammalian germ-line transgenesis by transposition. Proc Natl Acad Sci U S A. 2002, 99: 4495-4499. 10.1073/pnas.062630599.PubMed CentralView ArticlePubMed
- Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH: Viable offspring derived from fetal and adult mammalian cells. Nature. 1997, 385: 810-813. 10.1038/385810a0.View ArticlePubMed
- Rideout WM, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R: Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell. 2002, 109: 17-27.View ArticlePubMed
- Nagy A, Moens C, Ivanyi E, Pawling J, Gertsenstein M, Hadjantonakis AK, Pirity M, Rossant J: Dissecting the role of N-myc in development using a single targeting vector to generate a series of alleles. Curr Biol. 1998, 8: 661-664.View ArticlePubMed
- Dobie K, Mehtali M, McClenaghan M, Lathe R: Variegated gene expression in mice. Trends Genet. 1997, 13: 127-130. 10.1016/S0168-9525(97)01097-4.View ArticlePubMed
- Garrick D, Fiering S, Martin DI, Whitelaw E: Repeat-induced gene silencing in mammals. Nat Genet. 1998, 18: 56-59.View ArticlePubMed
- Smith MC, Thorpe HM: Diversity in the serine recombinases. Mol Microbiol. 2002, 44: 299-307. 10.1046/j.1365-2958.2002.02891.x.View ArticlePubMed
- Thorpe HM, Smith MC: In vitro site-specific integration of bacteriophage DNA catalyzed by a recombinase of the resolvase/invertase family. Proc Natl Acad Sci U S A. 1998, 95: 5505-5510. 10.1073/pnas.95.10.5505.PubMed CentralView ArticlePubMed
- Sauer B, Henderson N: Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome. Nucleic Acids Res. 1989, 17: 147-161.PubMed CentralView ArticlePubMed
- Orban PC, Chui D, Marth JD: Tissue- and site-specific DNA recombination in transgenic mice. Proc Natl Acad Sci U S A. 1992, 89: 6861-6865.PubMed CentralView ArticlePubMed
- Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K: Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science. 1994, 265: 103-106.View ArticlePubMed
- Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D: Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res. 1999, 27: 4324-4327. 10.1093/nar/27.22.4324.PubMed CentralView ArticlePubMed
- Cao T, Longley MA, Wang XJ, Roop DR: An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy. J Cell Biol. 2001, 152: 651-656. 10.1083/jcb.152.3.651.PubMed CentralView ArticlePubMed
- Weber P, Metzger D, Chambon P: Temporally controlled targeted somatic mutagenesis in the mouse brain. Eur J Neurosci. 2001, 14: 1777-1783. 10.1046/j.0953-816x.2001.01803.x.View ArticlePubMed
- Kellendonk C, Tronche F, Casanova E, Anlag K, Opherk C, Schutz G: Inducible site-specific recombination in the brain. J Mol Biol. 1999, 285: 175-182. 10.1006/jmbi.1998.2307.View ArticlePubMed
- Minamino T, Gaussin V, DeMayo FJ, Schneider MD: Inducible gene targeting in postnatal myocardium by cardiac-specific expression of a hormone-activated Cre fusion protein. Circ Res. 2001, 88: 587-592.View ArticlePubMed
- Lakso M, Sauer B, Mosinger B, Lee EJ, Manning RW, Yu SH, Mulder KL, Westphal H: Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci U S A. 1992, 89: 6232-6236.PubMed CentralView ArticlePubMed
- Araki K, Araki M, Miyazaki J, Vassalli P: Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase. Proc Natl Acad Sci U S A. 1995, 92: 160-164.PubMed CentralView ArticlePubMed
- de Wit T, Drabek D, Grosveld F: Microinjection of cre recombinase RNA induces site-specific recombination of a transgene in mouse oocytes. Nucleic Acids Res. 1998, 26: 676-678. 10.1093/nar/26.2.676.PubMed CentralView ArticlePubMed
- Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, Reth M: Inducible site-directed recombination in mouse embryonic stem cells. Nucleic Acids Res. 1996, 24: 543-548. 10.1093/nar/24.4.543.PubMed CentralView ArticlePubMed
- Utomo AR, Nikitin AY, Lee WH: Temporal, spatial, and cell type-specific control of Cre-mediated DNA recombination in transgenic mice. Nat Biotechnol. 1999, 17: 1091-1096. 10.1038/15073.View ArticlePubMed
- Vasioukhin V, Degenstein L, Wise B, Fuchs E: The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc Natl Acad Sci U S A. 1999, 96: 8551-8556. 10.1073/pnas.96.15.8551.PubMed CentralView ArticlePubMed
- Tronche F, Casanova E, Turiault M, Sahly I, Kellendonk C: When reverse genetics meets physiology: the use of site-specific recombinases in mice. FEBS Lett. 2002, 529: 116-121. 10.1016/S0014-5793(02)03266-0.View ArticlePubMed
- Rodriguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, Ayala R, Stewart AF, Dymecki SM: High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet. 2000, 25: 139-140. 10.1038/75973.View ArticlePubMed
- Schaft J, Ashery-Padan R, van der Hoeven F, Gruss P, Stewart AF: Efficient FLP recombination in mouse ES cells and oocytes. Genesis. 2001, 31: 6-10. 10.1002/gene.1076.View ArticlePubMed
- Meyers EN, Lewandoski M, Martin GR: An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat Genet. 1998, 18: 136-141.View ArticlePubMed
- Andreas S, Schwenk F, Kuter-Luks B, Faust N, Kuhn R: Enhanced efficiency through nuclear localization signal fusion on phage PhiC31-integrase: activity comparison with Cre and FLPe recombinase in mammalian cells. Nucleic Acids Res. 2002, 30: 2299-2306. 10.1093/nar/30.11.2299.PubMed CentralView ArticlePubMed
- Page RL, Canseco RS, Russell CG, Johnson JL, Velander WH, Gwazdauskas FC: Transgene detection during early murine embryonic development after pronuclear microinjection. Transgenic Res. 1995, 4: 12-17.View ArticlePubMed
- Belteki G, Gertsenstein M, Ow DW, Nagy A: Site-specific cassette exchange and germline transmission with mouse ES cells expressing phiC31 integrase. Nat Biotechnol. 2003, 21: 321-324. 10.1038/nbt787.View ArticlePubMed
- Sclimenti CR, Thyagarajan B, Calos MP: Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res. 2001, 29: 5044-5051. 10.1093/nar/29.24.5044.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.